Skip to content

Effect of Licorice extracts in the treatment of Melasma

Effect of Licorice extracts in the treatment of Melasma: randomized, double-blinded and placebo-controlled clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016040316016N2
Enrollment
44
Registered
2016-04-11
Start date
2014-09-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma or Chloasma. Other disorders of pigmentation

Interventions

Intervention 1: In intervention group: Treatment with cream of solid lipid nano particles containing licorice extracts 4%, BID (day and night) on the lesion along with cream sunscreen SPF=35. Interven
Treatment - Drugs
Placebo
In intervention group: Treatment with cream of solid lipid nano particles containing licorice extracts 4%, BID (day and night) on the lesion along with cream sunscreen SPF=35
In control group: Treatment with cream placebo, BID (day and night) on lesion along with cream sunscreen SPF=35.

Sponsors

Kerman University of Medical Sciences, Deputy of research and technology
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- Patients with melasma clinically diagnosed 2- Women patients 3- Age between 20 to 40 years old 4- Patients with one lesion at least 5- Those don,t use any treatment for melasma during the six months prior to commencement of the study. Exclusion criteria: 1- Pregnant women 2- Lactating women 3- Those under treatment with other drugs for melasma during the six months prior to commencement of the study 4- Patients with history of allergy to licorice extracts 5- Treatment with oral contraceptives during of the study 6- Those under treatment with any drug for other diseases.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Size of lesions. Timepoint: Before and after intervention. Method of measurement: Examination.;Number of lesions. Timepoint: Before and after intervention. Method of measurement: Examination.;Location of lesions. Timepoint: Before intervention. Method of measurement: Examination.;Quality of life. Timepoint: Before and after intervention. Method of measurement: Questionare MELASQOL and DLQI.;Response to treatment. Timepoint: Before intervention and then at 4, 8 and 12 weeks. Method of measurement: Examination.;Course of the disease. Timepoint: Before intervention. Method of measurement: Questionare.;Wood,s lamp examination. Timepoint: Before intervention. Method of measurement: Examination.

Secondary

MeasureTime frame
Side effects. Timepoint: After intervention. Method of measurement: Examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSiavash Mohammadzadeh Shanehsaz

Kerman University of Medical Sciences

mdsiavash@yahoo.com+98 34 3325 7560

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026